



Estimated GFR and the Effect of Intensive Blood Pressure Lowering After Acute Intracerebral Hemorrhage

Danni Zheng, BPharm,^{1,2} Shoichiro Sato, MD, PhD,¹ Hisatomi Arima, MD, PhD,^{1,2,3} Emma Heeley, PhD,^{1,2} Candice Delcourt, MD,^{1,2,4} Yongjun Cao, MD,^{1,5} John Chalmers, MD, PhD,^{1,2} and Craig S. Anderson, MD, PhD,^{1,2,4} on behalf of the INTERACT2 Investigators*

Background: The kidney-brain interaction has been a topic of growing interest. Past studies of the effect of kidney function on intracerebral hemorrhage (ICH) outcomes have yielded inconsistent findings. Although the second, main phase of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2) suggests the effectiveness of early intensive blood pressure (BP) lowering in improving functional recovery after ICH, the balance of potential benefits and harms of this treatment in those with decreased kidney function remains uncertain.

Study Design: Secondary analysis of INTERACT2, which randomly assigned patients with ICH with elevated systolic BP (SBP) to intensive (target SBP < 140 mm Hg) or contemporaneous guideline-based (target SBP < 180 mm Hg) BP management.

Setting & Participants: 2,823 patients from 144 clinical hospitals in 21 countries.

Predictors: Admission estimated glomerular filtration rates (eGFRs) of patients were categorized into 3 groups based on the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) creatinine equation: normal or high, mildly decreased, and moderately to severely decreased (>90, 60-90, and <60 mL/min/1.73 m², respectively).

Outcomes: The effect of admission eGFR on the primary outcome of death or major disability at 90 days (defined as modified Rankin Scale scores of 3-6) was analyzed using a multivariable logistic regression model. Potential effect modification of intensive BP lowering treatment by admission eGFR was assessed by interaction terms.

Results: Of 2,623 included participants, 912 (35%) and 280 (11%) had mildly and moderately/severely decreased eGFRs, respectively. Patients with moderately/severely decreased eGFRs had the greatest risk for death or major disability at 90 days (adjusted OR, 1.82; 95% CI, 1.28-2.61). Effects of early intensive BP lowering were consistent across different eGFRs ($P = 0.5$ for homogeneity).

Limitations: Generalizability issues arising from a clinical trial population.

Conclusions: Decreased eGFR predicts poor outcome in acute ICH. Early intensive BP lowering provides similar treatment effects in patients with ICH with decreased eGFRs.

Am J Kidney Dis. 68(1):94-102. © 2016 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

INDEX WORDS: Kidney function; estimated glomerular filtration rate (eGFR); chronic kidney disease (CKD); dialysis; hemodialysis; stroke; intracerebral hemorrhage (ICH); cerebral hemorrhage; stroke; cerebrovascular disease; systolic blood pressure; intensive blood pressure lowering treatment; INTERACT2.

Patients with cerebrovascular disease often have chronic kidney disease (CKD), chiefly defined as reduced estimated glomerular filtration rate (eGFR) or increased urinary albumin excretion, because of shared risk factors and pathophysiologic mechanisms

affecting the brain and kidney.¹ Although mounting evidence indicates an association between reduced kidney function and adverse outcomes in patients with acute stroke, much of these data pertain to those with ischemic or undifferentiated stroke.²⁻⁴ Thus, the

From ¹The George Institute for Global Health; ²Sydney Medical School, University of Sydney, Sydney, Australia; ³Center for Epidemiologic Research in Asia, Shiga University of Medical Sciences, Otsu, Japan; ⁴Royal Prince Alfred Hospital, Sydney, Australia; and ⁵Department of Neurology, The Second Affiliated Hospital of Suzhou University, Suzhou, China.

*A full list of INTERACT2 Investigators appears in the Acknowledgements.

Received November 1, 2015. Accepted in revised form January 17, 2016. Originally published online March 3, 2016.

Trial registration: www.ClinicalTrials.gov; study number: NCT00716079.

Address correspondence to Craig S. Anderson, MD, PhD, The George Institute for Global Health, PO Box M201, Missenden Road, Camperdown, NSW 2050, Australia. E-mail: canderson@georgeinstitute.org.au

© 2016 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

0272-6386

<http://dx.doi.org/10.1053/j.ajkd.2016.01.020>

prognostic significance of kidney function in patients with acute intracerebral hemorrhage (ICH), the most serious type of stroke, remains uncertain. Although the second, main phase of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2) did not demonstrate a significant reduction in the combined primary outcome of 90-day death or major disability by intensive blood pressure (BP) treatment at the conventional $P < 0.05$ level, it showed improved secondary functional recovery, as measured by changes across all levels of the modified Rankin Scale (mRS) scores. These findings have led to revisions of guidelines,^{5,6} but concerns persist over the potential for harm from such treatment (eg, in patients with poor kidney function). The objectives of this study were to elucidate the prognostic significance of decreased eGFR in more than 2,600 participants in INTERACT2⁵ and assess whether it modifies the treatment effect of early intensive BP lowering.

METHODS

Study Design and Patient Characteristics

This was a post hoc analysis of the INTERACT2 study population, the details of which are outlined elsewhere.⁵ In brief, INTERACT2 was an international, multicenter, open, blinded end point–assessed, randomized, controlled trial involving 2,839 patients with acute spontaneous ICH within 6 hours of onset and elevated systolic BP (SBP; 150–220 mm Hg). Participants were randomly assigned to receive intensive (target SBP < 140 mm Hg within 1 hour) or contemporaneous guideline-recommended (target SBP < 180 mm Hg) BP-lowering therapy using locally available agents according to standardized protocols. Patients were excluded if they had a structural cerebral cause for the ICH, were in a deep coma (defined as Glasgow Coma Scale scores of 3–5), had a massive ICH with an expected poor prognosis, or early surgery to evacuate the hematoma was planned. The study protocol was approved by an appropriate ethics committee at each hospital site, and written informed consent was obtained from each participant or his or her legal surrogate.

Demographic and clinical characteristics were recorded at the time of enrollment. Initial laboratory parameters, including serum creatinine, were measured at hospital presentation/admission. Assessment of kidney function was based on eGFR calculated using the CKD-EPI (CKD Epidemiology Collaboration) creatinine equation.⁷ Because creatinine level was not standardized to isotope-dilution mass spectrometry, the INTERACT2 creatinine level was reduced by 5% for calculations using the CKD-EPI equation.⁸ Participants were categorized into 3 groups of eGFRs: normal or high, mildly decreased, and moderately to severely decreased (>90 , 60–90, and <60 mL/min/1.73 m², respectively).⁹ BP was measured in the nonparetic arm with the patient supine using an automated device or manual sphygmomanometer with an appropriate size cuff. Baseline BP was measured twice with an interval of 2 or fewer minutes and the mean of the 2 measurements was used. Achieved BP in the hyperacute phase was measured at 1, 6, 12, 18, and 24 hours postrandomization; mean values of these 5 measurements were calculated. A diagnostic computed tomographic (CT) scan was obtained for all participants according to standardized techniques at baseline and at a mean of 24 ± 3 (standard deviation) hours in a subset of patients where this was routine or for a substudy evaluating hematoma growth. For each

CT scan, uncompressed digital CT images were collected in Digital Imaging and Communications in Medicine (DICOM) format on a CD-ROM identified only with the patient's unique study number. Hematoma and perihematomal edema volumes were independently assessed by trained neurologists (S.S., C.D., Y.C.) who were blinded to clinical and treatment details and date and sequence of scan using computer-assisted multislice planimetric and voxel threshold techniques.^{10,11}

Outcomes

For these analyses, the primary clinical outcome was death or major disability at 90 days (defined by mRS scores of 3–6).¹² Secondary clinical outcomes were, separately, death and major disability (mRS scores of 6 and 3–5, respectively) at 90 days. CT outcomes in a subset of patients were absolute 24-hour hematoma and perihematomal edema growth volumes.

Statistical Analysis

Baseline characteristics of patients in predefined groups were summarized as mean \pm standard deviation or median with interquartile range for continuous variables and as number (percent) for categorical variables, with comparisons made using Wilcoxon or χ^2 tests. Associations between baseline eGFR and clinical outcomes were examined using categorical and ordinal logistic regression, using normal or high eGFR as the reference group and adjusted for potential confounders including: age, Chinese region, any history of ischemic stroke, acute coronary syndrome, hypertension, diabetes mellitus, prior use of antithrombotics and a statin, log-transformed time from onset to randomization, baseline SBP, baseline National Institutes of Health Stroke Scale score (<14 and ≥ 14), baseline hematoma volume (≤ 10 , 11–20, and >20 mL), location (lobar and nonlobar) of ICH, intraventricular extension of ICH, and randomly assigned group. We further tested potential effect modification by antithrombotic therapy on the relationship between kidney function and the primary outcome using interaction terms. Stratified analyses of antithrombotic users versus non–antithrombotic users were also carried out in logistic regression models. Heterogeneity of the treatment effect of intensive BP lowering between eGFR groups was also examined with the use of interaction terms. Effects of eGFR levels on mean achieved SBP during the initial 24 hours in each treatment arm were assessed by analysis of covariance adjusted for the same covariates except for randomized intensive BP lowering. The association between eGFR and 24-hour absolute growth of hematoma and perihematomal edema volumes was also determined using analysis of covariance; the 24-hour hematoma growth model was adjusted for recurrent ICH, warfarin use, time from onset to baseline CT scan, categorized baseline hematoma volume, and intraventricular extension of ICH.¹⁰ The 24-hour perihematomal edema growth model was adjusted for time from onset to CT scan, categorized baseline ICH volume, intraventricular extension of ICH, and 24-hour hematoma growth.¹¹ Data are reported as odds ratios (ORs) and 95% confidence intervals (CIs). A 2-tailed $P < 0.05$ was regarded as indicating statistical significance. All analyses were performed using SAS software (version 9.3; SAS Institute Inc).

RESULTS

A total of 2,623 patients with recorded admission creatinine level and 90-day clinical outcome were included in this study (Fig S1, available as online supplementary material). Characteristics for those included and excluded were broadly similar (Table S1). Of those included, 1,431 (55%), 912 (35%), and 280 (11%) patients had normal/high, mildly decreased, and moderately/severely decreased

eGFR, respectively. There were 9 patients who had received dialysis within 7 days of the hospital admission. In comparison to those with normal/high eGFRs, patients with decreased eGFRs tended to be older and were recruited from countries outside China. Patients with decreased eGFRs were more likely to have had a history of ischemic stroke, acute coronary syndrome, hypertension, and diabetes

mellitus and to have used antithrombotics and statins prior to ICH. Furthermore, they had higher SBP, National Institutes of Health Stroke Scale score, and ICH score values, with a greater proportion of intraventricular extension of ICH at admission and required a higher number of BP-lowering agents compared with patients with normal/high eGFRs (Table 1).

Table 1. Patient Characteristics According to Admission eGFR Categories

	Normal or High eGFR: >90 mL/min/1.73 m ²	Mildly Decreased eGFR: 60-90 mL/min/1.73 m ²	Moderately/Severely Decreased eGFR: <60 mL/min/1.73m ²	P
No. of patients	1,431	912	280	
Demographics				
Age, y	59 ± 11	70 ± 12	71 ± 14	<0.001
Male sex	900 (63)	568 (62)	172 (61)	0.9
Ethnicity				
Chinese ethnicity	1,073 (75)	518 (57)	154 (55)	<0.001
African ethnicity	16 (1)	8 (1)	4 (1)	0.7
Medical history				
ICH	118 (8)	70 (8)	26 (9)	0.7
Ischemic stroke	130 (9)	105 (12)	28 (10)	0.2
Acute coronary syndrome	27 (2)	34 (4)	15 (5)	0.001
Hypertension	1,020 (71)	663 (73)	223 (80)	0.02
Diabetes mellitus	125 (9)	108 (12)	54 (19)	<0.001
Medications				
Antihypertensives	566 (40)	468 (51)	161 (58)	<0.001
Antithrombotics	105 (7)	160 (18)	61 (22)	<0.001
Statin	65 (5)	97 (11)	32 (11)	<0.001
Clinical features				
Time from onset to randomization, h:min	3:41 [2:45-4:44]	3:47 [2:54-4:42]	3:38 [2:53-4:44]	0.6
SBP, mm Hg	178 ± 16	180 ± 17	183 ± 18	<0.001
DBP, mm Hg	103 ± 14	99 ± 15	100 ± 16	<0.001
ICH score	1 (0-1)	1 (0-2)	1 (0-2)	<0.001
NIHSS ≥ 14 ^a	444 (31)	315 (35)	119 (43)	<0.001
GCS ≤ 9 ^b	101 (7)	87 (10)	26 (9)	0.08
Serum creatinine, mg/dL	0.65 ± 0.15	0.89 ± 0.17	1.90 ± 1.60	<0.001
Baseline CT findings				
Hematoma volume, mL ^c	11.5 [6.1-19.8]	10.0 [5.0-18.7]	10.5 [5.8-19.6]	0.04
Hematoma location ^d				
Lobar	108 (8)	108 (13)	28 (11)	
Deep	1,113 (85)	692 (81)	206 (81)	
Brainstem	46 (4)	22 (3)	8 (3)	
Cerebellum	43 (3)	30 (4)	12 (5)	
Intraventricular extension of ICH ^e	329 (25)	261 (31)	92 (36)	<0.001
Perihematomal edema volume, mL ^e	1.8 [0.9-3.6]	1.8 [0.8-3.7]	2.4 [1.0-4.9]	0.1
Randomized intensive BP lowering	708 (49)	453 (50)	132 (47)	0.7
Treatment with ≥2 BP-lowering agents	645 (45)	448 (49)	145 (52)	0.04

Note: Values for categorical variables are given as number (percentage); values for continuous variables, as mean ± standard deviation or median [interquartile range].

Abbreviations: BP, blood pressure; CT, computed tomography; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; GCS, Glasgow Coma Scale; ICH, intracerebral hemorrhage; NIHSS, National Institutes of Health Stroke Scale; SBP, systolic blood pressure.

^aNIHSS scores can range from 0 (normal, no neurologic deficit) to 42 (coma with quadriplegia).

^bGCS scores can range from 3 (deep coma) to 15 (normal, alert).

^cThere were 195 total patients with missing baseline CT data.

^dThere were 207 total patients with missing information for baseline hematoma location.

^eThere were 1,827 total patients with missing information for baseline perihematomal edema volume.

Admission eGFR was associated with the primary combined clinical outcome of death or major disability and with the secondary clinical outcome of major disability alone. Compared with patients with normal/high eGFRs, those with moderately/severely decreased eGFRs had worse 90-day outcomes (adjusted OR, 1.82; 95% CI, 1.28-2.61; Table 2; Fig 1) and greater risk for major disability (adjusted OR, 1.51; 95% CI, 1.12-2.05; Table 2). However, moderately/severely decreased eGFR was not significantly associated with death (adjusted OR, 1.08; 95% CI, 0.70-1.67; Table 2). Ordinal logistic regression analyses using all levels of mRS scores¹² showed similar results (adjusted OR, 1.49; 95% CI, 1.15-1.93 for moderately/severely decreased eGFRs; *P* for trend = 0.01; Fig 1). Furthermore, our results did not show evidence of effect modification by antithrombotic use for the primary outcome of death or major disability (*P* = 0.6). Stratified analyses revealed statistically significant associations between admission eGFR and the primary outcome of death and major disability among non-antithrombotic users and associations for outcomes of death and major disability separately among antithrombotic users (Table S2).

There was no evidence of heterogeneity in the effect of early intensive BP-lowering treatment on the primary poor outcome (death or major disability at 90 days) across the 3 eGFR groups (*P* = 0.5 for homogeneity; Fig 2). Table S3 shows a significant inverse trend between mean achieved 24-hour SBP and

categories of eGFR in the treatment group (*P* for trend < 0.001).

A substantial number of patients were missing 24-hour CT imaging data. There were 923 patients with available hematoma growth data and 798 with perihematomal edema growth data (Fig S1). As shown in Table S4, there is no significant association between decreased eGFR and 24-hour hematoma and perihematomal edema growth (adjusted *P* for trend = 0.3 for both).

DISCUSSION

This study shows that reduced kidney function on admission is an independent predictor of poor outcome in patients with acute ICH, but this does not appear to be due to an effect of hematoma or perihematomal edema growth. However, there was no evidence of heterogeneity in the beneficial effect of early intensive BP lowering according to different eGFRs.

There is increasing awareness of the influence of kidney function on the outcome from acute stroke,^{2-4,13,14} with previous studies being largely consistent in showing that reduced kidney function has independent significance in ischemic or undifferentiated stroke.²⁻⁴ However, studies of the relationship between kidney function and outcomes in ICH are limited.¹⁴⁻¹⁸ A multicenter study of 113,059 patients with ICH in the United States reported an association between kidney dysfunction and higher in-hospital mortality,¹⁸ which confirmed results of other small studies of this

Table 2. Association Between Admission eGFR and Clinical Outcomes at 90 Days

Outcome/Admission eGFR	No. of Events (%)	Univariable		Multivariable	
		OR (95% CI)	<i>P</i> for trend	OR (95% CI)	<i>P</i> for trend
Death or major disability					
Normal or high eGFR ^a	661/1,431 (46)	1.00 (reference)	<0.001	1.00 (reference)	0.007 ^d
Mildly decreased eGFR ^b	529/912 (58)	1.61 (1.36-1.90)		1.04 (0.83-1.31)	
Moderately/severely decreased eGFR ^c	200/280 (71)	2.91 (2.20-3.85)		1.82 (1.28-2.61)	
Death					
Normal or high eGFR ^a	124/1,431 (9)	1.00 (reference)	<0.001	1.00 (reference)	0.8 ^d
Mildly decreased eGFR ^b	138/912 (15)	1.88 (1.45-2.43)		0.96 (0.69-1.34)	
Moderately/severely decreased eGFR ^c	49/280 (18)	2.24 (1.56-3.20)		1.08 (0.70-1.67)	
Major disability					
Normal or high eGFR ^a	537/1,431 (38)	1.00 (reference)	<0.001	1.00 (reference)	0.03 ^d
Mildly decreased eGFR ^b	391/912 (43)	1.25 (1.06-1.48)		1.01 (0.82-1.24)	
Moderately/severely decreased eGFR ^c	151/280 (54)	1.95 (1.51-2.52)		1.51 (1.12-2.05)	

Abbreviations: CI, confidence interval; eGFR; estimated glomerular filtration rate; OR, odds ratio.

^aeGFR >90 mL/min/1.73 m².

^beGFR of 60-90 mL/min/1.73 m².

^ceGFR <60 mL/min/1.73 m².

^dAdjusted for age, Chinese ethnicity, history of ischemic stroke, acute coronary syndrome, hypertension, diabetes mellitus, prior use of antithrombotics and statin, log-transformed time from onset to randomization, baseline systolic blood pressure, baseline National Institutes of Health Stroke Scale score (<14 and ≥14), hematoma volume (≤10, 11-20, and >20 mL) and location (lobar and non-lobar), intraventricular extension of intracerebral hemorrhage, and randomly assigned group.




Figure 1. Baseline estimated glomerular filtration rate (eGFR) and modified Rankin Scale (mRS) score at 90 days. Crude odds ratios (ORs) of ordinal logistic regression analysis, 1.65 (95% confidence interval [CI], 1.43-1.92) for group with mildly decreased eGFR; and 2.58 (95% CI, 2.05-3.24) for the group with moderately/severely decreased eGFR in comparison to the normal- or high-eGFR group (*P* for trend < 0.001). Adjusted ORs of ordinal logistic regression analysis, 1.04 (95% CI, 0.88-1.23) for the group with mildly decreased eGFR; and 1.49 (95% CI, 1.15-1.93) for the group with moderately/severely decreased eGFR in comparison to the normal- or high-eGFR group (*P* for trend = 0.01). ^a >90 mL/min/1.73 m². ^b 60-90 mL/min/1.73 m². ^c <60 mL/min/1.73 m².

topic.¹⁴⁻¹⁷ Nonetheless, these studies did not include data related to imaging findings¹⁶⁻¹⁸ or functional outcome^{14,15,18} and lacked the ability to fully adjust for confounding variables due to small sample sizes.¹⁴⁻¹⁷ Our study largely overcomes these limitations by being based on a large population of well-characterized patients from a wide range of hospitals across 21 countries, and we also adjusted for various important confounders, such as ICH volume, ICH location, and baseline clinical status, that are components of the predictive ICH and the Functional Outcome in Patients with Primary Intracerebral Hemorrhage (FUNC) scores,^{19,20} thus strengthening the evidence of an association between reduced kidney function and poor functional outcome in ICH.

The exact mechanisms underlying the relationship between reduced kidney function and poor outcomes after stroke are unknown, although some studies have proposed that it relates to effects on the initial size and growth of hematoma and perihematomal edema.^{15,17} However, we have been unable to show a significant association between eGFR and 24-hour growth in hematoma and perihematomal edema volume. Because patients with decreased eGFRs are generally older, premorbid frailty related to aging is a plausible contributing factor to poor outcomes irrespective of ICH dynamics.^{21,22} Other explanations include measures of brain frailty such as mild cognitive impairment and co-occurring depression, which is common in patients with CKD due to their high symptom




Figure 2. Effect of early intensive blood pressure lowering on death or major disability at 90 days by baseline estimated glomerular filtration rate (eGFR). Solid boxes represent estimates of treatment effect on risk for outcomes. Centers of the boxes are placed at the estimate of the effect; areas of the boxes are proportional to the reciprocal of the variance of the estimates. Horizontal lines represent 95% confidence interval (CIs); diamonds, estimates and 95% CIs for overall effects in total participants. INTERACT2 (Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial) had a reported odds ratio (OR) of 0.87 (95% CI, 0.75-1.01; *P* = 0.06) for the primary outcome of death or major disability with intensive treatment. Ordinal logistic regression analysis showed significantly lower modified Rankin Scale scores with intensive treatment (OR for greater disability, 0.87; 95% CI, 0.77-1.00; *P* = 0.04).⁵

burden and poor quality of life,^{23,24} that could adversely affect rehabilitation potential and functional outcomes after stroke.²⁵⁻²⁷ Prior studies have also shown that receiving maintenance hemodialysis is an independent indicator for poor functional outcome and mortality after stroke, possibly related to the presence of other comorbid conditions.^{28,29} Finally, decreased erythropoietin production leading to anemia in patients with CKD³⁰ may contribute to secondary cerebral injury caused by neuronal tissue hypoxia, metabolic distress, and cell energy dysfunction.^{31,32}

Decreased eGFR is a surrogate marker of cerebral small-vessel disease and is strongly associated with vascular risk factors.^{1,33} We speculated that moderately/severely decreased eGFR indicates altered cerebral regulation from more advanced cerebral small-vessel disease.^{1,23-35} In patients with stable cerebral autoregulation, decreases in cerebral perfusion pressure trigger compensatory vasodilation of resistance arterioles to preserve cerebral blood flow.³⁶ Conversely, autoregulatory failure may occur at higher cerebral perfusion pressures in patients with long-standing hypertension with altered cerebral autoregulation.³⁶ In the present analysis, the overall treatment effect was homogeneous across all eGFRs and the data do not show a deleterious effect of intensive BP lowering in groups with decreased eGFRs. Thus, our study supports findings of no relationship between the magnitude of BP reduction and perihematomal cerebral blood flow in patients with moderate ICH.³⁷ Intriguingly, the beneficial effect of intensive BP lowering appears to be marginally more pronounced in the group with normal or high eGFRs. This trend may be attributed to variations in achieved SBP during the initial 24 hours between eGFR groups due to possible BP treatment resistance in patients with decreased eGFRs (as evidenced by the higher number of BP-lowering agents required)^{38,39} and/or more cautious BP reduction management by physicians in more vulnerable patients.

We recognize that this study has some limitations, such as the inability to obtain information for kidney-specific factors, for example, proteinuria prior to ICH onset. Information for possible causes of poor ICH outcomes in patients with decreased eGFRs, such as premorbid physical and cognitive function, depression symptoms, and baseline hemoglobin levels or anemia condition, was also unavailable. Due to the limited number of hemodialysis patients in the study, we were also unable to assess its contribution to the prognosis of ICH. Furthermore, the present study includes patients from around the world and thus the CKD-EPI equation, which was developed using a sample of North American and European populations, may have led to overestimation of baseline

kidney function measurements (especially in the Asian population) and biased results toward the null. Finally, because the data are derived from a clinical trial population in which patients with a poor prognosis and large hematoma were excluded, there may be concerns of the generalizability of the findings.

In summary, these analyses of the INTERACT2 database highlight the adverse prognostic significance of decreased admission eGFRs in patients with ICH, which appears independent of an effect of hematoma or perihematomal edema growth. However, early intensive BP-lowering treatment provides broadly consistent effects, even in patients with ICH with decreased eGFRs.

ACKNOWLEDGEMENTS

The INTERACT2 Investigators are as follows. Executive Committee: C.S. Anderson (principal investigator), J. Chalmers (chair), H. Arima, S. Davis, E. Heeley, Y. Huang, P. Lavados, B. Neal, M.W. Parsons, R. Lindley, L. Morgenstern, T. Robinson, C. Stapf, C. Tzourio, J.G. Wang. National Leaders: China—Steering Committee: Y. Huang (chair), S. Chen, X.Y. Chen, L. Cui, Z. Liu, C. Lu, J. Wang, S. Wu, E. Xu, Q. Yang, C. Zhang, J. Zhang. Europe—Austria: R. Beer, E. Schmutzhard; Belgium: P. Redondo; Finland: M. Kaste, L. Soenne, T. Tatlisumak; France: C. Stapf; Germany: K. Wartenberg; Italy: S. Ricci; the Netherlands: K. Klijn; Portugal: E. Azevedo; Spain: A. Chamorro; Switzerland: M. Arnold, U. Fischer; India: S. Kaul, J. Pandian, H. Boyini, S. Singh. North America: A.A. Rabinstein. South America—Argentina: C. Estol; Brazil: G. Silva; Chile: P. Lavados, V.V. Olavarria. United Kingdom: T.G. Robinson. Data Safety and Monitoring Committee: R.J. Simes (chair), M.-G. Bousser, G. Hankey, K. Jamrozik (deceased), S.C. Johnston, S. Li. Project Office Operations Committee: E. Heeley (study director), C.S. Anderson, K. Bailey, J. Chalmers, T. Cheung, C. Delcourt, S. Chintapatla, E. Ducasse, T. Erho, J. Hata, B. Holder, E. Knight, R. Lindley, M. Leroux, T. Sassé, E. Odgers, R. Walsh, Z. Wolfowicz. Endpoint Adjudication Committee: C.S. Anderson, G. Chen, C. Delcourt, S. Fuentes, R. Lindley, B. Peng, H.-M. Schneble, M.-X. Wang. Statistical Analysis: H. Arima, L. Billot, S. Heritier, Q. Li, M. Woodward. CT Analyses: C. Delcourt (chair), S. Abimbola, S. Anderson, E. Chan, G. Cheng, P. Chmielnik, J. Hata, S. Leighton, J.-Y. Liu, B. Rasmussen, A. Saxena, and S. Tripathy. Data Management and Programming: M. Armenis, M.A. Baig, B. Naidu, G. Starzec, S. Steley. Coordinating Centers: International (The George Institute for Global Health, Sydney, Australia): C.S. Anderson, E. Heeley, M. Leroux, C. Delcourt, T. Sassé, E. Knight, K. Bailey, T. Cheung, E. Odgers, E. Ducasse, B. Holder, Z. Wolfowicz, R. Walsh, S. Chintapatla, T. Erho; Argentina, Buenos Aires (STAT Research): C. Estol, A. Moles, A. Ruiz, M. Zimmermann; Brazil, Fortaleza (Medicamenta MRS): J. Marinho, S. Alves, R. Angelim, J. Araujo, L. Kawakami; Chile, Santiago (Clínica Alemana, Universidad del Desarrollo): P. Lavados, V.V. Olavarria, C. Bustos, F. Gonzalez, P. Munoz Venturelli; China, Beijing (The George Institute China incorporating George Clinical, and Peking University First Hospital): Y. Huang, X. Chen, Y. Huang, R. Jia, N. Li, S. Qu, Y. Shu, A. Song, J. Sun, J. Xiao, Y. Zhao; China, Shanghai (The Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine): J.G. Wang, Q. Huang; Europe, Paris (Unité de Recherche Clinique, APHP-Hôpital Lariboisière): C. Stapf, E. Vicaut, A. Chamam, M.-C. Viaud, C. Dert, U. Fiedler, V. Jovis, S. Kabla, S. Marchand, A.

Pena, V. Rochaud; India, Hyderabad (The George Institute India): K. Mallikarjuna H. Boyini, N. Hasan; Norway, Oslo (Oslo University Hospital): E. Berge, E.C. Sandset, A.S. Forårsveen; United Kingdom (Department of Cardiovascular Sciences, University of Leicester): T. Robinson, D. Richardson, T. Kumar, S. Lewin; United Kingdom (London, Imperial Clinical Trials Unit): N. Poulter, J. Field, A. Anjum, A. Wilson. Principal Investigators and Coordinators (according to country and center): Argentina—Clínica Instituto Medico Adroque: H. Perelmuter, A.M. Agarie; Hospital Central de Mendoza: A.G. Barboza, L.A. Recchia, I.F. Miranda, S.G. Rauek, R.J. Duplessis; Australia—Austin Hospital: H. Dewey, L. Walker, S. Petrolo; Box Hill: C. Bladin; Gosford Hospital: J. Sturm, D. Crimmins, D. Griffiths, A. Schutz, V. Zenteno; John Hunter Hospital: M.W. Parsons, F. Miteff, N. Spratt, E. Kerr, C.R. Levi; Monash Medical Centre: T.G. Phan, H. Ma, L. Sanders, C. Moran, K. Wong; Royal Brisbane and Women's Hospital: S. Read, R. Henderson, A. Wong, R. Hull, G. Skinner; Royal Melbourne Hospital: S. Davis, P. Hand, B. Yan, H. Tu, B. Campbell; Royal Prince Alfred Hospital: C.S. Anderson, C. Delcourt; Sir Charles Gairdner Hospital: D.J. Blacker; Western Hospital: T. Wijeratne, M. Pathirage, M. Jasinararchchi, Z. Matkovic, S. Celestino; Austria—Allgemeines Krankenhaus Linz: F. Gruber, M.R. Vosko, E. Diabl, S. Rathmaier; Innsbruck Medical University—Department of Neurology: R. Beer, E. Schmutzhard, B. Pfäusler, R. Helbok; Medical University of Graz, Department of Neurology: F. Fazekas, R. Fischer, B. Poltrum, B. Zechner, U. Trummer; Belgium—Cliniques De L'Europe (Europe Clinic): M.P. Rutgers; UCL St Luc: A. Peeters, A. Dusart, M.-C. Duray, C. Parmentier, S. Ferrao-Santos; Universitair Ziekenhuis Brussel: R. Brouns, S. De Raedt, A. De Smedt, R.-J. VanHooff, J. De Keyser; Brazil—Hospital das Clínicas de Porto Alegre: S.C.O. Martins, A.G. de Almeida, R. Broudani, N.F. Titton; Hospital Quinta D'Or: G.R. de Freitas, F.M. Cardoso, L.M. Giesel, N.A. Lima Jr; Hospital Santa Marcelina: A.C. Ferraz de Almeida, R.B. Gomes, T.S. Borges dos Santos, E.M. Veloso Soares, O.L.A. Neto; Universidade Federal de São Paulo: G.S. Silva, D.L. Gomes, F.A. de Carvalho, M. Miranda, A. Marques; Universidade Federal do Paraná: V.F. Zétola, G. de Matia, M.C. Lange; Chile—Clínica Alemana de Santiago: J. Montes, A. Reccius, P. Munoz Venturelli, V.V. Olavarria, A. Soto; Clínica Alemana de Temuco, Chile: R. Rivas, C. Klapp; Clínica Dávila: S. Illanes, C. Aguilera, A. Castro; Complejo Asistencial Dr. Víctor Ríos Ruiz: C. Figueroa, J. Benavides, P. Salamanca, M.C. Concha, J. Pajarito; Hospital Naval Almirante Nef: P. Araya, F. Guerra; China—Baotou Central Hospital: Y. Li, G. Liu, B. Wang, J. Zhang, Y. Chong; Beijing Shijitan Hospital: M. He, L. Wang, J. Liu; Beijing Tongren Hospital: X. Zhang, C. Lai, H. Jiang, Q. Yang, S. Cui; Chang Ning District Central Hospital: Q. Tao, Y. Zhang, S. Yao, M. Xu, Y. Zhang; Changsha Central Hospital: Z. Liu, H. Xiao, J. Hu, J. Tang; Gongli Hospital, Pudong New Area, Shanghai: J. Sun, H. Ji, M. Jiang; Haidian Hospital, Beijing: F. Yu, Y. Zhang, X. Yang, X. Guo; Hejian City People's Hospital: Y. Wang, L. Wu, Z. Liu, Y. Gao, D. Sun; Hunan Province Brain Hospital: X. Huang, Y. Wang, L. Liu, Y. Li, P. Li; Jiangsu Province Hospital of Traditional Chinese Medicine: Y. Jiang, H. Li, H. Lu; Nanjing First Hospital: J. Zhou, C. Yuan; Navy General Hospital: X. Qi, F. Qiu, H. Qian, W. Wang, J. Liu; Peking University First Hospital: Y. Huang, W. Sun, F. Li, R. Liu, Q. Peng; Peking University Shougang Hospital: Z. Ren, C. Fan, Y. Zhang, H. Wang, T. Wang; People's Hospital of Beijing Daxing District: F. Shi, C. Duan, S. Chen, J. Wang, Z. Chen; Pinggu County Hospital, Beijing: X. Tan, Z. Zhao, Y. Gao, J. Chen, T. Han; Qinghai Province People's Hospital: S. Wu, L. Zhang, L. Wang, Q. Hu, Q. Hou; Qinghai University Affiliated Hospital: X. Zhao, L. Wang, G. Zeng, L. Ma, F. Wang; Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine: S. Chen, L. Zeng, Z. Guo, Y. Fu, Y. Song; Second Hospital of Hebei Medical University: L. Tai, X. Liu, X. Su, Y. Yang, R. Dong; Shijiazhuang 260 Hospital: Y. Xu, S. Tian, S. Cheng, L. Su, X. Xie; The Affiliated Hospital of Xuzhou Medical College: T. Xu, D. Geng, X. Yan, H. Fan, N. Zhao; The Branch Hospital of the First People's Hospital: S. Wang, J. Yang; The Chinese PLA No. 263 Hospital: J. Zhang, M. Yan, L. Li; The Fifth Affiliated Hospital Sun Yat-Sen University: Z. Li, X. Xu, F. Wang; The First Affiliated Hospital of Baotou Medical College: L. Wu, X. Guo, Y. Lian, H. Sun, D. Liu; The First Affiliated Hospital of Fujian Medical University: N. Wang, Q. Tang; The First Affiliated Hospital of Wenzhou Medical College: Z. Han, L. Feng; The Fourth Hospital of Jilin University: Y. Cui, J. Tian, H. Chang, X. Sun, J. Wang; The Second Affiliated Hospital Suzhou University: C. Liu, Z. Wen; The Second Affiliated Hospital of Guangzhou Medical College: E. Xu, Q. Lin; The Second Affiliated Hospital of Wenzhou Medical College: X. Zhang, L. Sun, B. Hu, M. Zou, Q. Bao; The Second Hospital of Qinghuangdao: X. Lin, L. Zhao, X. Tian, H. Wang, X. Wang; The Second Hospital of Tianjin Medical University: X. Li, L. Hao, Y. Duan, R. Wang, Z. Wei; Third Hospital of Hebei Medical University: J. Liu, S. Ren, H. Ren, Y. Wang, Y. Dong; Tianjin Medical University General Hospital: Y. Cheng, M. Zou, W. Liu, J. Han, C. Zhang; Tianjin Third Central Hospital: Z. Zhang, J. Zhu, Y. Wang, Q. Li; Traditional Chinese Medicine Hospital, Zhangjiagang: J. Qian, Y. Sun, K. Liu, F. Long; Wangcheng County People's Hospital of Hunan Province: X. Peng, Q. Zhang, Z. Yuan, C. Wang, M. Huang; Wuxi People's Hospital: J. Zhang, F. Wang, P. He, Y. You, X. Wang; Xiangya Hospital Central-South University: Q. Yang, H. Wang, J. Xia, L. Zhou, Y. Hou; Xining First People's Hospital: Y. Wang, L. Liu, Y. Qi, L. Mei, R. Lu; Xuzhou Central Hospital: G. Chen, L. Liu, L. Ping, W. Liu, S. Zhou; Yutian County Hospital, Hebei Province: J. Wang, L. Wang, H. Li, S. Zhang, L. Wang; Zengcheng People's Hospital: R. Zou, J. Guo, M. Li, W. Wei; Finland—Helsinki University Central Hospital: L. Soinne, S. Curtze, M. Saarela, D. Strbian, F. Scheperjans; France—Centre Hospitalier de Saint Denis, Hôpital Delafontaine: T. De Broucker, C. Henry, R. Cumurciuc, N. Iboș-Augé; Centre Hospitalier de Versailles André-Mignot: A.-C. Zéghoudi, F. Pico; CH Calais: O. Dereeper, M.-C. Simian, C. Boisselier, A. Mahfoud; CHRU de Brest: S. Timsit, F.M. Merrien; CHU de Nantes-Hôpital G&R Laënnec: B. Guillon, M. Sevin, F. Herisson, C. Magne; Hôpital de Meaux: A. Ameri, C. Cret, S. Stefanizzi, F. Klapczynski; Hôpital Kremlin Bicêtre: C. Denier, M. Sarov-Riviere; Hôpital Lariboisière: C. Stapf, P. Reiner, J. Mawet, D. Hervé, F. Buffon; Hôpital Ste-Anne: E. Touzé, V. Domingo, C. Lamy, D. Calvet, M. Pasquini; Hôpital Tenon: S. Alamowitch, P. Favrole, I.-P. Muresan; Pitié Salpêtrière: S. Crozier, C. Rosso, C. Pires, A. Leger, S. Deltour; Roger Salengro Lille: C. Cordonnier, H. Henon, C. Rossi; Service de Neurologie et Neurovasculaire, Groupe Hospitalier Paris Saint Joseph: M. Zuber, M. Bruandet, R. Tamazyan, C. Join-Lambert; Germany—Charité-University Medicine Berlin, Center for Stroke Research Berlin (CSB): E. Juetter, T. Krause, S. Maul, M. Endres, G.J. Jungehulsing; Department of Neurology University of Heidelberg UMM Mannheim: M. Hennerici, M. Griebe, T. Sauer, K. Knoll; Department of Neurology, University of Ulm: R. Huber, K. Knauer, C. Knauer, S. Raubold; Dresden University of Technology, University Hospital, Department of Neurology: H. Schneider, H. Hentschel, C. Lautenschläger, E. Schimmel, I. Dzialowski; Goethe University Hospital Frankfurt: C. Foerch, M. Lorenz, O. Singer, I.M. R. Meyer dos Santos; Klinikum Frankfurt (Oder): A. Hartmann, A. Hamann, A. Schacht, B. Schrader, A. Teichmann; Martin Luther University: K.E. Wartenberg, T.J. Mueller; University Hospital Düsseldorf: S. Jander, M. Gliem, C. Boettcher; University Medical Center Hamburg-Eppendorf: M. Rosenkranz, C. Beck, D. Otto, G. Thomalla, B. Cheng; Hong Kong—Prince of Wales Hospital, Chinese University of Hong Kong: K.S. Wong, T.W. Leung, Y.O.Y. Soo; India—Apollo Hospitals: S. Prabhakar, S.R.

Kesavarapu, P.K. Gajjela, R.R. Chenna; Baby Memorial Hospital: K. Ummer, M. Basheer, A. Andipet; CARE Hospital, Nampally: M.K.M. Jagarlapudi, A.U.R. Mohammed, V.G. Pawar, S.S.K. Eranki; Christian Medical College & Hospital: J. Pandian, Y. Singh, N. Akhtar; GNRC Hospitals: N.C. Borah, M. Ghose, N. Choudhury; Jehangir Clinical Development Centre Pvt Ltd: N.R. Ichaporla, J. Shendge, S. Khese; Lalitha Super Specialities Hospital: V. Pamidimukkala, P. Inbamuthaiah, S.R. Nuthakki, N.M.R. Tagallamudi, A.K. Gutti; Postgraduate Institute of Medical Education & Research: D. Khurana, P. Kesavarapu, V. Jogi, A. Garg, D. Samanta; St. John's Medical College & Hospital (1): G.R.K. Sarma, R. Nadig, T. Mathew, M.A. Anandan; Italy—Central follow up for Italy: E. Caterbi; Nuovo Ospedale Civile, AUSL Modena: A. Zini, M. Cavazzuti, F. Casoni, R. Pentore, F. Falzone; Ospedale di Branca: S. Ricci, T. Mazzoli, L.M. Greco, C. Menichetti, F. Coppola; Ospedale di Città di Castello: S. Cenciarelli, E. Gallinella, A. Mattioni, R. Conduro, I. Sicilia; San Giovanni Battista: M. Zampolini, F. Corea, M. Barbi, C. Proietti; Sapienza University Unità di Trattamento Neurovascolare: D. Toni, A. Pieroni, A. Anzini, A. Falcou, M. Demichele; the Netherlands—University Medical Center Utrecht (2): C.J.M. Klijn; Norway—Sørlandet Sykehus HF Kristiansand: A. Tveiten, E.T. Thortveit, S. Pettersen; Sykehuset Innlandet HF Lillehammer: N. Holand, B. Hitland; University Hospital North Norway: S.H. Johnsen, A. Eltoft; Pakistan—Aga Khan University: M. Wasay, A. Kamal, A. Iqar, L. Ali, D. Begum; Portugal—Centro Hospitalar Sao Joao: G. Gama, E. Azevedo, L. Fonseca, G. Moreira; Centro Hospitalar Vila Nova de Gaia: L.M. Veloso, D. Pinheiro, L. Paredes, C. Rozeira, T. Gregorio; Spain—Complejo Hospitalario Universitario de Albacete: T. Segura Martin, O. Ayo, J. Garcia-Garcia, I. Feria Vilar, I. Gómez Fernández; Hospital Clinico de Barcelona: A. Chamorro, S. Amaro, X. Urra, V. Obach, A. Cervera; Hospital Universitari de Girona, Dr Josep Trueta: Y. Silva, J. Serena, M. Castellanos, M. Terceno, C. Van Eendenburg; Switzerland—University of Bern, Inselspital: U. Fischer, M. Arnold, A. Weck, O. Findling, R. Lüdi; United Kingdom—Addenbrookes Hospital: E.A. Warburton, D. Day, N. Butler, E. Bumanlag; Bristol Royal Infirmary: S. Caine, A. Steele, M. Osborn, E. Dodd, P. Murphy; County Durham & Darlington NHS Foundation Trust: B. Esi, E. Brown, R. Hayman, V.K.V. Baliga, M. Minphone; John Radcliffe Hospital: J. Kennedy, I. Reckless, G. Pope, R. Teal, K. Michael; King's College Hospital: D. Manawadu, L. Kalra, R. Lewis, B. Mistry, E. Cattermole; Leeds General Infirmary: A. Hassan, L. Mandizvidza, J. Bamford, H. Brooks, C. Bedford; Musgrave Park Hospital: R. Whiting, P. Baines, M. Hussain, M. Harvey; New Cross Hospital: K. Fotherby, S. McBride, P. Bourke, D. Morgan, K. Jennings-Preece; Northumbria Healthcare—Wansbeck and North Tyneside General Hospitals: C. Price, S. Huntley, V.E. Riddell, G. Storey, R.L. Lakey; Nottingham University Hospital: G. Subramanian; Royal Bournemouth Hospital: D. Jenkinson, J. Kwan, O. David, D. Tiwari; Royal Devon and Exeter Hospital: M. James, S. Keenan, H. Eastwood; Royal United Hospital Bath NHS Trust: L. Shaw, P. Kaye, D. Button, B. Madigan, D. Williamson; Royal Victoria Infirmary Hospital NHS Foundation Trust: A. Dixit, J. Davis, M.O. Hossain, G.A. Ford; Salford Royal NHS Foundation Trust: A. Parry-Jones, V. O'Loughlin, R. Jarapa, Z. Naing; St George's Healthcare NHS Trust: C. Lovelock, J. O'Reilly, U. Khan; St. Thomas Hospital: A. Bhalla, A. Rudd, J. Birns; University College London Hospitals NHS Foundation Trust: D.J. Werring, R. Law, R. Perry, I. Jones, R. Erande; University Hospital of North Staffordshire: C. Roffe, I. Natarajan, N. Ahmad, K. Finney, J. Lucas; University Hospitals of Leicester NHS Trust: A. Mistri, D. Eveson, R. Marsh, V. Haunton, T. Robinson; United States—Mayo Clinic: A.A. Rabinstein, J.E. Fugate, S.W. Lepore.

Support: INTERACT2 was supported by Program (571281) and Project (512402 and 1004170) grants from the National Health and

Medical Research Council (NHMRC) of Australia. The NHMRC did not have any role in the study design; data collection, analysis, and interpretation; writing the report; or the decision to submit the report for publication.

Financial Disclosure: Dr Sato holds a fellowship from the Japan Brain Foundation. Dr Anderson reports receiving travel reimbursement and honorarium from Takeda China and Covidien.

Contributions: Research idea and study design: DZ, SS, HA; data acquisition: HA, EH, CD, YC, JC, CSA; data analysis/interpretation: DZ, SS, HA, EH, CD, YC, JC, CSA; statistical analysis: DZ, SS; supervision or mentorship: JA, CSA. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. CSA takes responsibility that this study has been reported honestly, accurately, and transparently; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned and registered have been explained.

Peer Review: Evaluated by 2 external peer reviewers, a Statistical Editor, a Co-Editor, and the Editor-in-Chief.

SUPPLEMENTARY MATERIAL

Table S1: Characteristics of included and excluded patients.

Table S2: Association between eGFR and clinical outcome by antithrombotic use.

Table S3: Mean achieved SBP within 24 h after treatment randomization.

Table S4: Association between eGFR and 24-h hematoma and perihematomal edema growth.

Figure S1: Patient flow chart.

Note: The supplementary material accompanying this article (<http://dx.doi.org/10.1053/j.ajkd.2016.01.020>) is available at www.ajkd.org

REFERENCES

1. Toyoda K, Ninomiya T. Stroke and cerebrovascular diseases in patients with chronic kidney disease. *Lancet Neurol*. 2014;13(8):823-833.
2. Yahalom G, Schwartz R, Schwammenthal Y, et al. Chronic kidney disease and clinical outcome in patients with acute stroke. *Stroke*. 2009;40(4):1296-1303.
3. Tsagalas G, Akrivos T, Alevizaki M, et al. Renal dysfunction in acute stroke: an independent predictor of long-term all combined vascular events and overall mortality. *Nephrol Dial Transplant*. 2009;24(1):194-200.
4. Ani C, Ovbiagele B. Relation of baseline presence and severity of renal disease to long-term mortality in persons with known stroke. *J Neurol Sci*. 2010;288(1-2):123-128.
5. Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. *N Engl J Med*. 2013;368(25):2355-2365.
6. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2015;46(7):2032-2060.
7. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150(9):604-612.
8. Skali H, Uno H, Levey AS, Inker LA, Pfeffer MA, Solomon SD. Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of

- Diet in Renal Disease Study equation. *Am Heart J*. 2011;162(3):548-554.
9. Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. *JAMA*. 2015;313(8):837-846.
 10. Wang X, Arima H, Al-Shahi Salman R, et al. Clinical prediction algorithm (BRAIN) to determine risk of hematoma growth in acute intracerebral hemorrhage. *Stroke*. 2015;46(2):376-381.
 11. Yang J, Arima H, Wu G, et al. Prognostic significance of perihematomal edema in acute intracerebral hemorrhage: pooled analysis from the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial studies. *Stroke*. 2015;46(4):1009-1013.
 12. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. *Stroke*. 1988;19(5):604-607.
 13. Yang J, Arima H, Zhou J, et al. Effects of low estimated glomerular filtration rate on outcomes after stroke: a hospital-based stroke registry in China. *Eur J Neurol*. 2014;21(8):1143-1145.
 14. Cutting S, Castro C, Lee VH, Prabhakaran S. Impaired renal function is not associated with increased volume of intracerebral hemorrhage. *J Stroke Cerebrovasc Dis*. 2014;23(1):86-90.
 15. Molshatzki N, Orion D, Tsabari R, et al. Chronic kidney disease in patients with acute intracerebral hemorrhage: association with large hematoma volume and poor outcome. *Cerebrovasc Dis*. 2011;31(3):271-277.
 16. Hao Z, Wu B, Lin S, et al. Association between renal function and clinical outcome in patients with acute stroke. *Eur Neurol*. 2010;63(4):237-242.
 17. Miyagi T, Koga M, Yamagami H, et al. Reduced estimated glomerular filtration rate affects outcomes 3 months after intracerebral hemorrhage: the stroke acute management with urgent risk-factor assessment and improvement-intracerebral hemorrhage study. *J Stroke Cerebrovasc Dis*. 2015;24(1):176-182.
 18. Ovbiagele B, Schwamm LH, Smith EE, et al. Hospitalized hemorrhagic stroke patients with renal insufficiency: clinical characteristics, care patterns, and outcomes. *J Stroke Cerebrovasc Dis*. 2014;23(9):2265-2273.
 19. Hemphill JC 3rd, Bonovich DC, Besmertis L, Manley GT, Johnston SC. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. *Stroke*. 2001;32(4):891-897.
 20. Rost NS, Smith EE, Chang Y, et al. Prediction of functional outcome in patients with primary intracerebral hemorrhage: the FUNC score. *Stroke*. 2008;39(8):2304-2309.
 21. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci*. 2001;56(3):M146-M156.
 22. Radholm K, Arima H, Lindley RI, et al. Older age is a strong predictor for poor outcome in intracerebral haemorrhage: the INTERACT2 study. *Age Ageing*. 2015;44(3):422-427.
 23. Palmer S, Vecchio M, Craig JC, et al. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. *Kidney Int*. 2013;84(1):179-191.
 24. Vecchio M, Palmer SC, Tonelli M, Johnson DW, Strippoli GF. Depression and sexual dysfunction in chronic kidney disease: a narrative review of the evidence in areas of significant unmet need. *Nephrol Dial Transplant*. 2012;27(9):3420-3428.
 25. Mok VC, Wong A, Lam WW, et al. Cognitive impairment and functional outcome after stroke associated with small vessel disease. *J Neurol Neurosurg Psychiatry*. 2004;75(4):560-566.
 26. Galski T, Bruno RL, Zorowitz R, Walker J. Predicting length of stay, functional outcome, and aftercare in the rehabilitation of stroke patients. The dominant role of higher-order cognition. *Stroke*. 1993;24(12):1794-1800.
 27. Ayerbe L, Ayis S, Crichton S, Wolfe CD, Rudd AG. The long-term outcomes of depression up to 10 years after stroke; the South London Stroke Register. *J Neurol Neurosurg Psychiatry*. 2014;85(5):514-521.
 28. Toyoda K, Fujii K, Fujimi S, et al. Stroke in patients on maintenance hemodialysis: a 22-year single-center study. *Am J Kidney Dis*. 2005;45(6):1058-1066.
 29. Sozio SM, Armstrong PA, Coresh J, et al. Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study. *Am J Kidney Dis*. 2009;54(3):468-477.
 30. Del Fabbro P, Luthi JC, Carrera E, Michel P, Burnier M, Burnand B. Anemia and chronic kidney disease are potential risk factors for mortality in stroke patients: a historic cohort study. *BMC Nephrol*. 2010;11:27.
 31. Kuramatsu JB, Gerner ST, Lucking H, et al. Anemia is an independent prognostic factor in intracerebral hemorrhage: an observational cohort study. *Crit Care*. 2013;17(4):R148.
 32. Lutz J, Menke J, Sollinger D, Schinzel H, Thurmel K. Haemostasis in chronic kidney disease. *Nephrol Dial Transplant*. 2014;29(1):29-40.
 33. Sedaghat S, Cremers LG, de Groot M, et al. Kidney function and microstructural integrity of brain white matter. *Neurology*. 2015;85(2):154-161.
 34. Purkayastha S, Fadar O, Mehregan A, et al. Impaired cerebrovascular hemodynamics are associated with cerebral white matter damage. *J Cereb Blood Flow Metab*. 2014;34(2):228-234.
 35. Yao H, Takashima Y, Hashimoto M, Uchino A, Yuzuriha T. Subclinical cerebral abnormalities in chronic kidney disease. *Contrib Nephrol*. 2013;179:24-34.
 36. Ruland S, Aiyagari V. Cerebral autoregulation and blood pressure lowering. *Hypertension*. 2007;49(5):977-978.
 37. Butcher KS, Jeerakathil T, Hill M, et al. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. *Stroke*. 2013;44(3):620-626.
 38. Tanner RM, Calhoun DA, Bell EK, et al. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. *Clin J Am Soc Nephrol*. 2013;8(9):1583-1590.
 39. De Nicola L, Gabbai FB, Agarwal R, et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. *J Am Coll Cardiol*. 2013;61(24):2461-2467.